Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA panel wants QT trials for NCEs

All new chemical entities should be evaluated clinically to determine if they cause QT prolongation, an FDA panel

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE